Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Image Added

A cross-disciplinary collaboration working to improve the content and implementation of clinical trial safety analyses for medical research, leading to better data interpretations and increased efficiency in the clinical drug development and review processes.

Working Group

...

Lead: Mary Nilsson
:
nilsson_mary_e@lilly.com

Image Modified

Research Advisor

Safety Analytics, Global Statistical Sciences, Eli, Lilly and Company

Mary received a MS degree in statistics from Iowa State University in 1989. She has been employed at Lilly since 1989 and is currently a research advisor in the Safety Analytics group within the Statistical Sciences function.
 
She consults with compound teams on
safety
safety analysis planning for Phase 2-3 studies and integrated submission documents.
 
Her primary interests include analyses of adverse event data, analyses of laboratory data, statistical analysis plans, and collection
and
of analysis of suicide-related events
.
Working Group Lead: Greg Ball
:
greg.ball@merck.com

Image Modified

After graduating

After graduating from Northwestern University with a
bachelor’s
bachelor's in economics,
Greg
Gregy served in the Navy for 4 years and taught high school math and physics for 5 years
,
before going back to school to get a
master’s
master's in applied statistics from Purdue University.
 
Eventually, while working as a statistician, he earned his PhD
in
in biostatistics from the University of Texas Health Science
Center
Centre.
 
His current research on blinded safety monitoring procedures emerged from his early work at academic medical
centers
centres (MD Anderson and the Methodist Hospital) and
CROs
CRO's (
Westat
West and Quintiles), developed into his college dissertation and continues to be developed in collaboration with statistical and clinical scientists from several pharmaceutical companies (Astellas, AbbVie and Merck).
 
Greg established, with Bill Wang, the ASA Biopharm Safety Monitoring
working group
Working Group and is pioneering the joint DIA-ASA Interdisciplinary Safety Evaluation (DAISE) scientific
working group
Working Group, to advocate for aggregate safety assessments and cross-disciplinary scientific engagement
.